drugset / Trial / NCT04129320
Enoblituzumab Plus MGA012 or MGD013 in Squamous Cell Carcinoma of the Head and Neck
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is an open-label study designed to evaluate safety and efficacy of enoblituzumab in combination with MGA012 or MGD013 in first-line treatment of patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN).
Timeline
- Start
- 2019-10
- Primary completion
- 2020-10
- Completion
- 2022-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Enoblituzumab | Monoclonal antibody | — | — |
| Subject | Retifanlimab | Monoclonal antibody | — | — |
| Subject | Tebotelimab | Protein / enzyme biologic | — | — |